Krystal Biotech (NASDAQ:KRYS) Announces Earnings Results

Krystal Biotech (NASDAQ:KRYS) issued its quarterly earnings data on Monday. The company reported $0.91 EPS for the quarter, beating the consensus estimate of $0.84 by $0.07, Briefing.com reports. The company had revenue of $83.84 million for the quarter, compared to analyst estimates of $82.94 million. Krystal Biotech had a return on equity of 1.99% and a net margin of 63.73%. Krystal Biotech’s quarterly revenue was up 879.9% compared to the same quarter last year. During the same period last year, the company earned ($0.67) earnings per share.

Krystal Biotech Stock Performance

Shares of Krystal Biotech stock opened at $170.85 on Tuesday. The business’s 50 day moving average price is $182.28 and its 200 day moving average price is $180.12. The company has a market cap of $4.91 billion, a price-to-earnings ratio of 46.81 and a beta of 0.82. Krystal Biotech has a one year low of $93.95 and a one year high of $219.34.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on the company. Evercore ISI increased their target price on Krystal Biotech from $201.00 to $206.00 and gave the company an “outperform” rating in a research report on Monday, August 12th. Stifel Nicolaus boosted their target price on shares of Krystal Biotech from $204.00 to $220.00 and gave the stock a “buy” rating in a research note on Wednesday, September 11th. William Blair upgraded shares of Krystal Biotech to a “strong-buy” rating in a research report on Friday, August 30th. Citigroup reiterated a “neutral” rating and issued a $204.00 price objective (up from $195.00) on shares of Krystal Biotech in a report on Tuesday, August 6th. Finally, Chardan Capital increased their target price on Krystal Biotech from $153.00 to $208.00 and gave the company a “buy” rating in a report on Monday, August 5th. One equities research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $196.75.

Insider Buying and Selling at Krystal Biotech

In other news, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction on Thursday, September 12th. The stock was sold at an average price of $197.76, for a total transaction of $4,944,000.00. Following the transaction, the insider now owns 1,500,882 shares in the company, valued at $296,814,424.32. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 14.10% of the stock is owned by company insiders.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).